L'intérêt à découvert pour Celularity donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Celularity. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Celularity (NASDAQ:CELU) Stock, Rapport sur les intérêts à découvert

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) narrows FY2024 sales outlook from $269.60 million-281.60 million to $272.60 million-278.60 million.

News

Guidance

UPLD

Upland Software Narrows FY2024 Sales Guidance from $269.60M-281.60M to $272.60M-278.60M  VS Est.274.57M

Vinci Partners Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $1.01 by 6.93 percent. The company reported quarterly sales of $112.716 million which beat the analyst consensus estimate of $110.552 million by 1.96 percent. This is a 414.00 percent increase over sales of $21.929 million the same period last year.

Earnings

Earnings Beats

VINP

Vinci Partners Inv Q3 2024 Adj. EPS $1.08 Beats $1.01 Estimate, Sales $112.716M Beat $110.552M Estimate

Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.17 by 23.53 percent. The company reported quarterly sales of $406.019 million which beat the analyst consensus estimate of $392.579 million by 3.42 percent. This is a 16.48 percent increase over sales of $348.571 million the same period last year.

Earnings Misses

GDOT

Green Dot Q3 2024 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $406.019M Beat $392.579M Estimate

Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.19) by 68.42 percent. This is a 135.29 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $46.77 million which beat the analyst consensus estimate of $41.95 million by 11.49 percent. This is a 5.86 percent decrease over sales of $49.69 million the same period last year.

CLFD

Clearfield Q4 EPS $(0.06) Beats $(0.19) Estimate, Sales $46.77M Beat $41.95M Estimate

Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) sees Q4 sales of $29.000 million-31.000 million vs $29.93 million estimate.

OUST

Ouster Sees Q4 Sales $29.000M-31.000M vs $29.93M Est

AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is looking for Q4 Adj EPS of $0.18-0.19 vs $0.01 analyst estimate. sees sales of $9.700 million-9.800 million vs $9.47 million estimate.

AEYE

AudioEye Sees Q4 Adj EPS $0.18-0.19 vs $0.01 Est; Sees Sales $9.700M-9.800M vs $9.47M Est

Business Outlook
Gary Yu further commented, "For the fourth quarter of 2024, we expect revenue to be approximately $337 million, plus or minus 3 percent, representing a 3.7% sequential decrease at the mid-point, slightly better than typical seasonality. GAAP gross margin is expected to be 33.0 percent, plus or minus 1 percent. Non-GAAP operating expenses, which are GAAP operating expenses adjusted for amortization of acquisition-related intangible assets, are expected to be approximately 28.0 percent of revenue, plus or minus 1 percent. We expect net interest income to be approximately $2.5 million. Our income tax rate is expected to be 18.0 percent, plus or minus 3 percent, and shares used to calculate diluted EPS for the fourth quarter are anticipated to be approximately 46.7 million."
Amortization of acquisition-related intangible assets of $3.1 million, after tax, for previous acquisitions is not included in these non-GAAP estimates.

DIOD

Diodes Inc. Sees Q4 Revenue ~$337M +/- 3% Vs $351.74M Est.

AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) raises FY2024 Adj EPS guidance from $0.51-0.53 to $0.54-0.55 vs $(0.13) analyst estimate. Raises FY2024 sales outlook from $35.15 million-35.25 million to $35.20 million-35.30 million vs $34.93 million estimate.

AudioEye Raises FY2024 Adj EPS Guidance from $0.51-0.53 to $0.54-0.55 vs $(0.13) Est; Raises FY2024 Sales Guidance from $35.15M-35.25M to $35.20M-35.30M vs $34.93M Est

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.56) by 25 percent.

LTRN

Lantern Pharma Q3 2024 GAAP EPS $(0.42) Beats $(0.56) Estimate

Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) sees Q4 sales of $65.900 million-71.900 million vs $67.71 million estimate.

Upland Software Sees Q4 Sales $65.900M-71.900M vs $67.71M Est

Dividends

VCTR

Victory Capital Holdings Increases Quarterly Cash Dividend From $0.41 To $0.44 Per Share

Tidewater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) reported quarterly earnings of $0.87 per share which missed the analyst consensus estimate of $1.09 by 20.18 percent. This is a 77.55 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $340.40 million which missed the analyst consensus estimate of $345.55 million by 1.49 percent. This is a 13.75 percent increase over sales of $299.26 million the same period last year.

Tidewater Q3 EPS $0.87 Misses $1.09 Estimate, Sales $340.40M Miss $345.55M Estimate

Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 56.52 percent. This is a 96.85 percent increase over losses of $(3.17) per share from the same period last year.

SKYE

Skye Bioscience Q3 2024 GAAP EPS $(0.10) Beats $(0.23) Estimate

Victory Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCTR#NASDAQ">VCTR</a>) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.30 by 3.85 percent. The company reported quarterly sales of $225.60 million which beat the analyst consensus estimate of $224.31 million by 0.58 percent. This is a 7.59 percent increase over sales of $209.69 million the same period last year.

Victory Capital Holdings Q3 2024 Adj EPS $1.35 Beats $1.30 Estimate, Sales $225.60M Beat $224.31M Estimate

Consensus Cloud Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) reported quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.29 by 1.55 percent. The company reported quarterly sales of $87.753 million which beat the analyst consensus estimate of $85.332 million by 2.84 percent. This is a 3.10 percent decrease over sales of $90.562 million the same period last year.

CCSI

Consensus Cloud Solutions Q3 2024 Adj. EPS $1.31 Beats $1.29 Estimate, Sales $87.753M Beat $85.332M Estimate

Q4 2024 Financial Outlook
For the fourth quarter of 2024, we expect total revenue to be in the range of $72 million to $76 million, of which approximately $11 million is expected to be tools revenue. We expect GAAP diluted EPS to be in the range of $(0.12) to $(0.06) and non-GAAP diluted EPS to be in the range of $(0.10) to $(0.04).
This outlook for non-GAAP diluted EPS excludes anticipated equity-based compensation expense of approximately $2.0 million. Non-GAAP diluted EPS should be considered in addition to, but not as a substitute for, our financial information presented in accordance with GAAP.

SKYT

SkyWater Technology Sees Q4 EPS $(0.10) - $(0.04) Vs $(0.03) Est.; Revenue $72M-$76M Vs $79.97M Est.

Airbnb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) reported third-quarter financial results Thursday after the bell. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/n41823683/airbnb-announces-third-quarter-2024-results">rundown of the report</a>.
Q3 Earnings: Airbnb reported third-quarter revenue of $3.70 billion, missing the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $3.72 billion. The company reported third-quarter earnings of $2.13 per share, missing analyst estimates of $2.16 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 10% year-over-year. Gross booking value totaled $20.1 billion, up 10% year-over-year. Nights and Experiences booked came in at $122.8 million, up 8% year-over-year.
Airbnb said it generated $1.1 billion of free cash flow during the quarter. The company ended the quarter with $11.3 billion in cash, cash equivalents, short-term investments and&nbsp;restricted cash.
&#8220;Airbnb had a strong Q3. Nights and Experiences Booked accelerated throughout the quarter and into Q4, despite a softer start due to shorter booking lead times compared to 2023,&#8221; the company said in a letter to shareholders.
&#8220;Building on robust momentum in September, we are off to a great start in fourth quarter 2024. We are seeing strong demand trends in Q4 2024 across core and expansion markets for both long and short lead times.&#8221;
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820744/9-stocks-to-watch-financial-sector-outshines-tech-in-2024-as-trump-trade-sparks-m-a">9 Stocks To Watch: Financial Sector Outshines Tech In 2024 As &#8216;Trump Trade&#8217; Sparks M&amp;A Optimism</a>
Outlook:&nbsp;Airbnb expects fourth-quarter revenue to be in the range of $2.39 billion to $2.44 billion. The company expects Nights and Experiences booked in the fourth quarter to be higher than in the third quarter. 
Airbnb anticipates full-year 2024 adjusted EBITDA margin of approximately 35.5% The company expects full-year free cash margin to be &#8220;several points above&#8221; adjusted EBITDA margins.
Airbnb executives will discuss the company&#8217;s quarterly results on a call with analysts and investors at 4:30 p.m. ET.
ABNB Price Action: <a href="https://www.benzinga.com/quote/ABNB" target="_blank" rel="noreferrer noopener">Airbnb shares</a> were down 2.08% in after-hours, trading at $142.50 at the time of publication Thursday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path"> • Fed Cuts Interest Rates To Lowest Since February 2023, Sticks To Data-Driven Path (CORRECTED)</a>
Photo: Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Airbnb Q3 2024 Earnings Call &#x7C; $ABNB" width="500" height="281" src="https://www.youtube.com/embed/RR_D086agzA?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Travel

After-Hours Center

Movers

General

ABNB

Airbnb Stock Down On Q3 Earnings: 'Building On Robust Momentum In September, We Are Off To A Great Start In Q4'

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) reported quarterly earnings of $1.61 per share which beat the analyst consensus estimate of $1.59 by 1.26 percent. This is a 20.15 percent increase over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $159.30 million which beat the analyst consensus estimate of $155.57 million by 2.40 percent. This is a 16.53 percent increase over sales of $136.71 million the same period last year.

COLL

Collegium Pharmaceutical Q3 Adj $1.61 Beats $1.59 Estimate, Sales $159.30M Beat $155.57M Estimate

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) affirms FY2024 sales outlook from $140.00 million-145.00 million to $140.00 million-145.00 million.

CUTR

Cutera Affirms FY2024 Sales Guidance to $140.00M-145.00M  VS Est.141.53M

Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) lowers FY2024 sales outlook from $450.00 million-470.00 million to $440.00 million-455.00 million.

PRCH

Porch Group Lowers FY2024 Sales Guidance from $450.00M-470.00M to $440.00M-455.00M

Celularity receives Nasdaq notice regarding late Form 10-K filing

Catalyst Watch: AI in the spotlight with Nvidia earnings, Microsoft Build, and an IBM event

Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing

Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His d...

Celularity Board Member Marc Mazur Announces Resignation

Celularity receives Nasdaq notice regarding late Form 10-Q filing

The latest announcement is out from Celularity (CELU). Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, f...

Celularity Announces Board Changes and New Indemnification Agreement

Celularity acquires Rebound product from Sequence Lifescience

Celularity receives Nasdaq notice, intends to file appeal

Celularity (CELU) issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by re...

Celularity to submit 510(k) notification for Tendon Wrap in early 2025

Celularity (CELU) has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding C...

Celularity files amended compliance plan with Nasdaq Hearings Panel

AAUKF

BYDDF

CELU

CELUW

DELL

DTRUY

MSFT

NGLOY

NKLA

NVDA

PANW

RIVN

SUPN

TMUS

TSLA

Press Releases

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Management

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Markets

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Provides Corporate Update

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

ImmuCell

MiNK Therapeutics

Longeveron

Lantern Pharma

Lumos Pharma

Marker Therapeutics

NextCure

Ocean Biomedical

SAB Biotherapeutics

Surrozen

vTv Therapeutics Inc. - Class A Common Stock

Comments

Celularity

Intérêt court

Celularity (NASDAQ:CELU) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL